MONMOUTH JUNCTION, N.J., June 6, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces that it has joined forces with investor relations firm, LifeSci Advisors, LLC to anchor its outreach to the broader investment community.
"We are delighted to be engaged with CytoSorbents to help create a comprehensive and impactful investor relations program," said Michael Rice, founder of LifeSci Partners. "The company has been successful in getting its CytoSorb blood purification technology onto the market in Europe, sales are on a positive growth trajectory, and there is a clear path to FDA approval in the U.S. As with all LifeSci Partners clients, we see this relationship as a partnership, and we look forward to collaborating with Dr. Phillip Chan and his team to raise the company's profile and attract new institutional and retail investors."
Dr. Phillip Chan, CEO of CytoSorbents stated, "We have been greatly impressed with the robust infrastructure and extensive network of healthcare investors, analysts, bankers, and other key resources that LifeSci Advisors brings to bear for its clients. LifeSci has an outstanding track record of recruiting excellent people with strong ties to Wall Street, and excels in organizing non-deal roadshows, research, corporate communications, key opinion leader events, broker meetings, and other activities that help companies such as ours rise above the noise. As a company commercializing our CytoSorb blood purification technology in 43 countries worldwide, we believe we can leverage their capabilities, particularly their physical international presence in major financial hubs such as London, Switzerland, and Israel, to rapidly spread our message to investors in the U.S. and around the globe. We are excited to move ahead with Michael and his team."
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 43 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety and efficacy of free hemoglobin reduction with intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 23,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $19 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Investor Relations Contact:
Public Relations Contact:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytosorbents---a-leader-in-blood-purification-to-treat-deadly-inflammation---teams-with-investor-relations-firm-lifesci-advisors-300469432.html
SOURCE CytoSorbents Corporation